119 related articles for article (PubMed ID: 10806999)
1. Oligonucleotide therapeutics for hematologic disorders.
Agarwal N; Gewirtz AM
Biochim Biophys Acta; 1999 Dec; 1489(1):85-96. PubMed ID: 10806999
[TBL] [Abstract][Full Text] [Related]
2. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
3. Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
Gewirtz AM
Leuk Lymphoma; 1993; 11 Suppl 1():131-7. PubMed ID: 7504543
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise?
de Fabritiis P; Calabretta B
Haematologica; 1995; 80(4):295-9. PubMed ID: 7590496
[No Abstract] [Full Text] [Related]
5. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
[TBL] [Abstract][Full Text] [Related]
6. Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems.
Clark RE
Leukemia; 2000 Mar; 14(3):347-55. PubMed ID: 10720125
[TBL] [Abstract][Full Text] [Related]
7. Myb targeted therapeutics for the treatment of human malignancies.
Gewirtz AM
Oncogene; 1999 May; 18(19):3056-62. PubMed ID: 10378701
[TBL] [Abstract][Full Text] [Related]
8. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
9. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides.
Ratajczak MZ; Kant JA; Luger SM; Hijiya N; Zhang J; Zon G; Gewirtz AM
Proc Natl Acad Sci U S A; 1992 Dec; 89(24):11823-7. PubMed ID: 1281545
[TBL] [Abstract][Full Text] [Related]
10. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K
Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654
[TBL] [Abstract][Full Text] [Related]
11. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
Smetsers TF; Skorski T; van de Locht LT; Wessels HM; Pennings AH; de Witte T; Calabretta B; Mensink EJ
Leukemia; 1994 Jan; 8(1):129-40. PubMed ID: 8289478
[TBL] [Abstract][Full Text] [Related]
12. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
Skorski T; Nieborowska-Skorska M; Nicolaides NC; Szczylik C; Iversen P; Iozzo RV; Zon G; Calabretta B
Proc Natl Acad Sci U S A; 1994 May; 91(10):4504-8. PubMed ID: 8183938
[TBL] [Abstract][Full Text] [Related]
13. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
Smetsers TF; van de Locht LT; Pennings AH; Wessels HM; de Witte TM; Mensink EJ
Leukemia; 1995 Jan; 9(1):118-30. PubMed ID: 7845006
[TBL] [Abstract][Full Text] [Related]
14. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
15. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
16. Anti-Bcl2 therapy in chronic myelogenous leukemia.
Smith S
Leuk Lymphoma; 2008 Jul; 49(7):1232-3. PubMed ID: 18604712
[No Abstract] [Full Text] [Related]
17. Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
Vaerman JL; Lewalle P; Martiat P
Stem Cells; 1993 Oct; 11 Suppl 3():89-95. PubMed ID: 8298481
[TBL] [Abstract][Full Text] [Related]
18. Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes.
Skorski T; Nieborowska-Skorska M; Campbell K; Iozzo RV; Zon G; Darzynkiewicz Z; Calabretta B
J Exp Med; 1995 Dec; 182(6):1645-53. PubMed ID: 7500009
[TBL] [Abstract][Full Text] [Related]
19. Oligonucleotide N3'-->P5' phosphoramidates as antisense agents.
Gryaznov S; Skorski T; Cucco C; Nieborowska-Skorska M; Chiu CY; Lloyd D; Chen JK; Koziolkiewicz M; Calabretta B
Nucleic Acids Res; 1996 Apr; 24(8):1508-14. PubMed ID: 8628685
[TBL] [Abstract][Full Text] [Related]
20. The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses.
Spiller DG; Giles RV; Broughton CM; Grzybowski J; Ruddell CJ; Tidd DM; Clark RE
Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):281-93. PubMed ID: 9743466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
